With humble beginnings as a pharmaceutical producer in 1973, HanAll Biopharma has come a long way, expanding its reach and impact in the Korean market by providing affordable medicines to patients. Fast forward to today, HanAll Biopharma has made remarkable strides in the global biopharma industry with its promising pipeline, which has the potential to make a meaningful contribution to patients’ lives.
In the early 2000s, HanAll Biopharma boldly underwent a transformation to become a biopharmaceutical company,
setting up cutting-edge laboratories in Seoul and Suwon and incorporating HanAll Pharmaceutical International (HPI) in Maryland, USA.
During this period, Seung-kook Park, the head of Daewoong Pharma's biolab, who led the development of Easyef Solution, joined HanAll,
bringing with him invaluable expertise in the field of biotechnology.
(HanAll Biolab)
In a move to bolster its R&D capabilities, HanAll formed a partnership with Nautilus Biotech, a French biopharmaceutical company, in 2007.
The company later acquired Nautilus in 2009 and integrated Resistein, an amino acid engineering technology that has since become a critical component in its pipelines. HanAll Biopharma allocates an impressive 15% of its annual sales earnings towards R&D initiatives and prioritizes research and development as part of its business model.
In fact, the company ranked second among all pharmaceutical companies in terms of R&D investment as a percentage of sales in 2012.
HanAll's unrelenting dedication to developing new drugs paid off after entering into a joint management with Daewoong Pharmaceutical in 2015.
The company made headlines in 2017 when it signed license agreements for its anti-FcRn asset HL161 with Harbour BioMed and Roivant Sciences, securing Korea's largest-ever antibody drug out-licensing contract worth $525 million with the latter. HanAll's impressive achievements have been widely recognized, with the company receiving multiple awards, including the Prime Minister's Commendation for the Korea New Growth Management Grand Prize in 2017 and the Korea New Drug Development Technology Export Award in 2019.
(Presentation of Korea New Growth Management Grand Prize, 2017)
(HanAll Biopharma-Harbour BioMed Technology Export Agreement Signing Ceremony, 2017)